Source: Nutrition 21, Inc.
New Study Shows Chromium Picolinate and Biotin Combination Significantly Reduces Fasting Blood Glucose in People with Type 2 Diabetes
Monday June 7, 9:31 am ET - Source: Yahoo news
Results From Diachrome(TM) Clinical Trial Presented at American Diabetes Association Scientific Sessions
ORLANDO, Fla., June 7 /PRNewswire-FirstCall/ -- (Nutrition 21, Inc. Nasdaq: NXXI) -- Results from a new human clinical trial show that daily nutritional supplementation with a combination of chromium picolinate and biotin (marketed as Diachrome) significantly reduced fasting blood glucose levels in patients who had type 2 diabetes for at least one year. The results, which evaluated 25 people over 30 days, were presented today at the American Diabetes Association (ADA) 64th Annual Scientific Sessions in Orlando.
The new randomized, double-blind, placebo-controlled trial found significant improvements in blood sugar control in patients who had baseline post-prandial blood glucose (PBG) levels above 200 mg/dL, and HbA1c levels greater than or equal to 7% and added Diachrome to their diabetes treatment regimen:
* Fasting Blood Glucose (FBG) levels significantly decreased by an
average of 26.2 mg/dL; the significant drop was observed in over 70%
of subjects taking Diachrome, compared with just 27% in the placebo
group (p < 0.01).
* Fructosamine Levels showed a mean decrease in the subjects taking
Diachrome of -32.4 micron M/L, while placebo group levels increased
by +7.73 micorn M/L. The difference between groups approached
significance (p< 0.07), and therefore warrants further study. The
fructosamine test provides a measure of average blood glucose levels
over several weeks, offering an additional tool to evaluate ongoing
"These results indicate that Diachrome should be considered a valuable adjunct therapy for type 2 diabetes patients whose blood sugar levels are not tightly controlled through oral anti-hyperglycemic medications and/or diet and exercise," states Jeffrey Geohas, MD, principal investigator, medical director, Radiant Research, Inc., Chicago. "Diachrome shows effectiveness in improving two important measures of ongoing blood glucose control."
According to Anne Daly, MS, RD, BC-ADM, CDE, leading author and expert in diabetes care and education, "Maintaining tight blood sugar control helps reduce the risk of long-term complications often associated with diabetes, and improves quality of life for patients." Daily adds, "The evidence supports Diachrome as a nutritional therapy that is not only safe and effective, but also affordable and convenient to use."
Additional data from the trial were reported on May 6th at an American Heart Association conference. The study found that Diachrome supplementation also provided significant improvement in coronary risk factors, including total cholesterol levels, LDL ("bad") cholesterol levels and lipid ratios.
"These outcomes indicate that Diachrome can have dramatic short term health benefits that could lead to improved and more affordable patient care," said Gail Montgomery, President and CEO of Nutrition 21, the company that contracted the study. "Over the coming months, we hope to bring forward a conclusive body of evidence that will encourage the healthcare community to adopt Diachrome as a standard nutrient therapy in diabetes care."
There are 18.2 million people in the United States who have diabetes. Complications of poor blood glucose control in people with type 2 diabetes, include heart disease and stroke, blindness, nerve damage, kidney damage and amputation.
About Nutrition 21
Nutrition 21 is a nutrition bioscience company, which develops and markets nutritional products, with health benefits substantiated by clinical research. The Company markets Chromax, the leading brand of chromium, and holds 35 patents for nutrition products, 22 for chromium compounds and their uses. For more information, visit http://www.nutrition21.com or http://www.diachrome.com or call 1-866-DIACHROME.
Nutrition 21 commissioned the study through Radiant Research, Inc. The results were presented as part of an ADA conference session on nutrition and diabetes, by Manley Finch, Associate Director Clinical Research at Nutrition 21, Inc.
Source: Nutrition 21, Inc.